These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 20055489)

  • 1. Novel application of 2D and 3D-similarity searches to identify substrates among cytochrome P450 2C9, 2D6, and 3A4.
    Freitas RF; Bauab RL; Montanari CA
    J Chem Inf Model; 2010 Jan; 50(1):97-109. PubMed ID: 20055489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.
    Wang B; Yang LP; Zhang XZ; Huang SQ; Bartlam M; Zhou SF
    Drug Metab Rev; 2009; 41(4):573-643. PubMed ID: 19645588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2D SMARTCyp reactivity-based site of metabolism prediction for major drug-metabolizing cytochrome P450 enzymes.
    Liu R; Liu J; Tawa G; Wallqvist A
    J Chem Inf Model; 2012 Jun; 52(6):1698-712. PubMed ID: 22631565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting drug metabolism by cytochrome P450 2C9: comparison with the 2D6 and 3A4 isoforms.
    Rydberg P; Olsen L
    ChemMedChem; 2012 Jul; 7(7):1202-9. PubMed ID: 22593031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes.
    Postlind H; DanielsonA ; Lindgren A; Andersson SH
    Drug Metab Dispos; 1998 Apr; 26(4):289-93. PubMed ID: 9531513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions.
    Stringer RA; Strain-Damerell C; Nicklin P; Houston JB
    Drug Metab Dispos; 2009 May; 37(5):1025-34. PubMed ID: 19196847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand-based models for the isoform specificity of cytochrome P450 3A4, 2D6, and 2C9 substrates.
    Terfloth L; Bienfait B; Gasteiger J
    J Chem Inf Model; 2007; 47(4):1688-701. PubMed ID: 17608404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing small-molecule binding to cytochrome P450 2D6 and 2C9: An in silico protocol for generating toxicity alerts.
    Rossato G; Ernst B; Smiesko M; Spreafico M; Vedani A
    ChemMedChem; 2010 Dec; 5(12):2088-101. PubMed ID: 21038340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development.
    Mori K; Hashimoto H; Takatsu H; Tsuda-Tsukimoto M; Kume T
    Xenobiotica; 2009 Jun; 39(6):415-22. PubMed ID: 19480547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classification of cytochrome p(450) activities using machine learning methods.
    Hammann F; Gutmann H; Baumann U; Helma C; Drewe J
    Mol Pharm; 2009; 6(6):1920-6. PubMed ID: 19813762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm.
    Ito K; Hallifax D; Obach RS; Houston JB
    Drug Metab Dispos; 2005 Jun; 33(6):837-44. PubMed ID: 15897600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel incubation direct injection LC/MS/MS technique for in vitro drug metabolism screening studies involving the CYP 2D6 and the CYP 3A4 isozymes.
    Bhoopathy S; Xin B; Unger SE; Karnes HT
    J Pharm Biomed Anal; 2005 Apr; 37(4):739-49. PubMed ID: 15797796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450.
    Zhao XJ; Yokoyama H; Chiba K; Wanwimolruk S; Ishizaki T
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1327-34. PubMed ID: 8968357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of Metabolism Prediction Models for CYP450 3A4, 2D6, and 2C9 Based on Microsomal Metabolic Reaction System.
    He SB; Li MM; Zhang BX; Ye XT; Du RF; Wang Y; Qiao YJ
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27735849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of cytochrome P450 3A4, 2D6, and 2C9 inhibitors and substrates by using support vector machines.
    Yap CW; Chen YZ
    J Chem Inf Model; 2005; 45(4):982-92. PubMed ID: 16045292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classification of cytochrome P450 inhibitors and noninhibitors using combined classifiers.
    Cheng F; Yu Y; Shen J; Yang L; Li W; Liu G; Lee PW; Tang Y
    J Chem Inf Model; 2011 May; 51(5):996-1011. PubMed ID: 21491913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of machine learning models for cytochrome P450 3A4, 2D6, and 2C9 inhibition.
    Gong C; Feng Y; Zhu J; Liu G; Tang Y; Li W
    J Appl Toxicol; 2024 Jul; 44(7):1050-1066. PubMed ID: 38544296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin.
    Colburn DE; Giles FJ; Oladovich D; Smith JA
    Hematology; 2004 Jun; 9(3):217-21. PubMed ID: 15204103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using chemical bond-based method to predict site of metabolism for five biotransformations mediated by CYP 3A4, 2D6, and 2C9.
    Fu X; He S; Du L; Lv Z; Zhang Y; Zhang Q; Wang Y
    Biochem Pharmacol; 2018 Jun; 152():302-314. PubMed ID: 29588194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.